Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TachoSil

Phase 3Small molecule

TachoSil is one of 86 small molecule programs targeting Age. It is currently in Phase 3.

2

Indications

11

Total Trials

1

Active Trials

85

Competitors

Pipeline

Status by Indication[3][1]

Indication

AgeCompleted

HemorrhageUnknown status

AgePreclinical

Completed

HemorrhagePhase 3

Unknown status

Competition

Competitive Landscape

61 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Plavix

Savaysa

Prevacid

Eliquis

Bristol-Myers Squibb

Bayer Aspirin

Klor-Con

Ketalar

Boehringer Ingelheim

Coumadin

Decadron

AAspen Global Incorporated

Doptelet

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Hemorrhage

NCT06664775

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection

Completed·AAesculap AG·Phase 4·NCT00918619·128 enrolled

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Completed· Takeda logo

Takeda·Phase 3·NCT01500135·150 enrolled

Hemorrhage2 trials

The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)

Unknown status·—·Phase 4·NCT02629510·268 enrolled

An Open Label, Prospective, Randomized, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of TachoSil® Versus Surgicel™ Original (Oxidized Regenerated Cellulose) as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery.

Recruiting·CCorza Medical GmbH·Phase 3·NCT06664775·116 enrolled

Surgery1 trial

GATT-Patch Versus TachoSil in Liver Surgery

Completed·GGATT Technologies BV·N/A·NCT05385952·132 enrolled

Pediatric Patients1 trial

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Completed· Takeda logo

Takeda·Phase 3·NCT01192022·253 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery

Completed·MMallinckrodt·Phase 3·NCT02284256·150 enrolled

4 more indications

Age1 trial

Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses

Completed·RR. van Hillegersberg·N/A·NCT02105506·15 enrolled

Liver Transplant1 trial

Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial

Unknown status·MMedical University of Warsaw·Phase 4·NCT06124209·170 enrolled

Pilot Study1 trial

Observational Pilot Study With TachoSil as a Ventricular Sealant

Completed·GGermans Trias i Pujol Hospital··NCT05717335·20 enrolled

Colorectal1 trial

Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM)

Completed·NNycomed·Phase 2·NCT00713661·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for TachoSil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TachoSil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TachoSil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Related News